Press Releases
Please, enter cell line, author or any other phrase or word you would like to search for.
Investerarträff 28 maj 2019
Phase Holographic Imaging, inbjuder till investerarträff för befintliga aktieägare och övriga intresserade tisdagen den 28 maj 2019 klockan 16:30 i bolagets lokaler, Scheelevägen 22 i Lund.
PHI establish US subsidiary to foster US partnerships
As part of the ongoing expansion of activities on the US market, the Board of Directors of Phase Holographic Imaging (PHI) has initiated the process of establishing a fully owned subsidiary in the US.
PHI releases App Suite 2 – more apps and greater applicability
App Suite 2 is the second release in a series of planned App Suite releases, developed to provide automated live-cell studies to researchers worldwide in an unprecedented user-friendly workflow, using PHI’s HoloMonitor-technology.
Chairman Klas Cramborn has passed away after a period of illness
PHI expands European distributor network
System-c bioprocess, Aurogene and Labsoft have recently been appointed to respectively represent Phase Holographic Imaging (PHI) in France, Italy and Poland.
Leading life science tools company enters technology assessment agreement with PHI
A major publicly traded life science tools company has entered a technology assessment agreement with Phase Holographic Imaging (PHI). The purpose of the agreement is to assess PHI’s Holo¬Monitor technology for cell biology applications, primarily within immuno-oncology.
PHI and BioSpherix expand marketing partnership after scientific evaluation
In June 2018, Phase Holographic Imaging (PHI) and BioSpherix Medical entered a collaboration agreement, aiming to co-market the companies’ complementary product lines. BioSpherix develops and market advanced hermetically sealed cell incubators for the control and optimization of cell culture environments.
Cancer researchers use HoloMonitor to track skin cancer cells
Scientists at the Holographic Imaging Cytometry Center of Excellence at University of California, San Francisco, study how normal skin cells transform into aggressive skin cancer. HoloMonitor M4 plays an important role in their research.
Lund University and PHI partner to develop novel 3D cell culturing methods for immunotherapy research
Based on PHI’s current HoloMonitor technology, the Department of Immunotechnology at Lund University and Phase Holographic Imaging (PHI) recently agreed to jointly develop novel 3-dimensional cell culturing methods to meet the urgent need for such methods.
Rights issue enables market expansion
The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.